Reported EBIDTA declined by 22.1% year-on-year (YoY) to Rs 45.2 crore while reported EBIDTA margin contracted by 800 basis points YoY to 21% in Q1 FY27.
Profit before tax in Q1 FY27 stood at Rs 17.5 crore, down by 60.9% from Rs 44.8 crore in Q1 FY26.
The company's net debt as on 30 June 2026 was Rs 398 crore. Post-IPO, the net debt stood at Rs 326 crore as on 20 September 2026.
Anil Satwani, chairman & managing director, Symbiotec Pharmalab, said: “Our first results as a listed company reflect a business with a steady growing core and two new growth engines for the future.
The API business — built over three decades of steroid chemistry depth and regulated-market presence — delivered steady revenue growth of 6% and EBITDA growth of 9%. Consistent, cash-generative growth here is what allows us to build the new growth engines with conviction.
In Complex Injectables, we filed our first ANDA from our Dual Chamber Vial platform this quarter — one more step closer to commercialization and are progressing well towards a second filing in the coming months. Behind these filings sits a pipeline that is getting deeper: our development work is steadily adding new molecules to the DCV portfolio and opening adjacent formats, extending the platform into new therapeutic segments.
In Biotech - CDMO Services, engagement is widening steadily. New customers are exploring manufacturing programmes across our capabilities, and existing conversations are progressing favourably. This is a business built on trust and technical credibility — these innovator customers take time to build the relationship, but are very sticky delivering a highly predictable, recurring revenue stream through take-or-pay arrangements.'
Symbiotec Pharmalab is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables.
The scrip rose 0.31% to currently trade at Rs 1162 on the BSE.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."